ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4

Journal of Coastal Life Medicine

# The Relevance of Acute Phase Reactants in Dermatology

**Received:** 24 October 2022, **Revised:** 23 November 2022, **Accepted:** 27 December 2022

**Dr. Nilkhil Girish, Dr Mohan Kale, Dr Gauri Bhale**
Department of Dermatology, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad –415110,Maharashtra

## Key Words:
acute phase reactants, dermatology, inflammation, biomarkers, C-reactive protein, psoriasis.

## Abstract:
Liver proteins called "Acute Phase Reactants (APRs)" respond to inflammation, infection, and tissue injury. APRs are biomarkers for psoriasis, systemic lupus erythematosus, hidradenitis suppurativa, vitiligo, rosacea, and autoimmune bullous disorders like pemphigus vulgaris and bullous pemphigoid.

CRP is a well-studied APR. Psoriasis and lupus erythematosus have high CRP values. Serum CRP levels correlate with psoriasis severity and may be a treatment target. CRP also indicates disease activity in lupus.

Hidradenitis suppurativa, a chronic skin condition, causes painful nodules, abscesses, and sinus tracts in the axillary, inguinal, and anogenital areas. Hidradenitis suppurativa patients exhibit high APRs, particularly CRP, which correspond with disease severity.

Vitiligo, an autoimmune disorder, causes skin regions to lose colour. Vitiligo patients had higher haptoglobin and ceruloplasmin levels.

Rosacea causes facial flushing, erythema, papules, and pustules. APRs including serum amyloid A, alpha-1-antitrypsin, and haptoglobin may be rosacea biomarkers.

Autoantibodies targeting skin structure proteins cause blistering and erosion in autoimmune bullous disorders. Pemphigus vulgaris and bullous pemphigoid patients had increased CRP and haptoglobin.

In conclusion, APRs have emerged as important biomarkers in dermatology, providing valuable information about disease activity, severity, and response to therapy. While more research is needed to fully understand the role of APRs in skin diseases, their potential as diagnostic and therapeutic targets is promising.

## 1. Introduction:

The liver produces proteins known as "acute phase reactants (APRs)" in reaction to tissue damage, infection, or inflammation. Dermatologists have discovered that APRs can be used as biomarkers for a variety of skin conditions, including rosacea, vitiligo, hidradenitis suppurativa, psoriasis, systemic lupus erythematosus, pemphigus vulgaris, and bullous pemphigoid [1].

"C-reactive protein (CRP)" is among the APRs that has received the most research. CRP levels have been found to be elevated in a variety of inflammatory skin conditions, including lupus erythematosus and psoriasis. Serum CRP levels have been linked to the severity of the psoriasis condition, and CRP has been suggested as a potential treatment target. CRP has also been discovered to be a helpful marker for disease activity in lupus erythematosus. A chronic inflammatory skin condition known as hidradenitis suppurativa causes recurrent painful nodules, abscesses, and sinus tracts in the axilla, inguinal, and anogenital areas. Patients with hidradenitis suppurativa have been reported to have increased levels of several APRs, including CRP, and it has been demonstrated that these levels are correlated with the severity of the disease [2,3].

An autoimmune condition called vitiligo causes patches of skin to become depigmented due to the loss of pigment-producing cells. According to studies, patients with vitiligo had higher serum levels of APRs such haptoglobin and ceruloplasmin. Rosacea is an inflammatory skin condition that causes papules, pustules, erythema, and face flushing. Several potential serum biomarkers for rosacea have been discovered through transcriptome analysis of facial skin, including APRs like serum amyloid A, alpha-1-antitrypsin, and haptoglobin. A set of skin conditions known as autoimmune bullous illnesses are caused by autoantibodies that target structural proteins in the skin and are characterized by erosions and blistering. Patients with pemphigus vulgaris and bullous

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

pemphigoid have been shown to have higher levels of serum APRs such CRP and haptoglobin [4-10].

In conclusion, APRs have become significant biomarkers in dermatology, offering useful data on the occurrence, severity, and response to treatment of disease. APRs have a role in skin illnesses, but further study is needed to fully understand this. Nevertheless, their potential as a target for diagnostic and therapeutic purposes is encouraging.

## 2. Pathophysiology of APRs

A set of proteins known as acute phase reactants (APRs) are produced in response to tissue damage, infection, and inflammation. In reaction to pro-inflammatory cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-), they are made by hepatocytes and other cells. The production of APRs is a component of the acute phase response, a systemic reaction to tissue damage and inflammation that is defined by modifications in the concentrations of different circulating proteins [1].

The acute phase response is mediated by a number of intricate mechanisms that are implicated in the pathophysiology of APRs. Pro-inflammatory cytokines including IL-1, IL-6, and TNF- are produced in greater quantities during the acute phase response, which activates intracellular signalling pathways that result in the production of APRs. The release of transcription factors including nuclear factor kappa B (NF-B) and activator protein 1 (AP-1) that bind to the promoter regions of APR genes and activate their transcription is stimulated by these cytokines [4,5].

Positive and negative APRs are two different types of APRs that are created during the acute phase response. Positive APRs are proteins whose levels rise in response to inflammation and tissue damage, including C-reactive protein (CRP), serum amyloid A (SAA), and fibrinogen. Proteins whose levels drop during the acute phase response are known as negative APRs. Examples include albumin and transferrin. The most popular positive APR and a sign of systemic inflammation is CRP. It attaches to bacterial and damaged cells, activating the classical complement system and promoting macrophage phagocytosis. Rheumatoid arthritis, inflammatory bowel disease, and sepsis are just a few of the inflammatory and infectious conditions that have been linked to elevated CRP levels [6-8].

Hepatocytes and monocytes create SAA, another positive APR, in response to pro-inflammatory cytokines. It has been demonstrated to have pro-inflammatory effects by increasing the production of adhesion molecules, cytokines, and chemokines. Atherosclerosis and systemic lupus erythematosus are two inflammatory illnesses that have been linked to elevated SAA levels. A positive APR that is essential to the coagulation cascade is fibrinogen. Hepatocytes produce it in reaction to pro-inflammatory cytokines, and it is transformed into fibrin during the clotting process. An elevated risk of cardiovascular disease and stroke has been linked to elevated fibrinogen levels [7-9].

The most prevalent protein in plasma is albumin, a negative APR produced by the liver. It performs a variety of tasks, such as maintaining oncotic pressure, transporting hormones and medications, and acting as an antioxidant. Albumin levels fall during the acute phase response as a result of decreased synthesis and increased degradation. Poor prognosis has been linked to a number of illnesses, including cancer and sepsis, and low albumin levels. Another negative APR implicated in transporting iron is transferrin, which is produced by the liver. It binds to iron and moves it to other tissues, including the liver and bone marrow. Transferrin levels fall during the acute phase response as a result of decreased synthesis and increased catabolism [6-10].

The acute phase response as a whole has significant physiological and pathological effects in addition to the functions played by individual APRs. APRs, cytokines, and complement proteins are just a few of the circulating proteins whose levels alter during the acute phase response. Activation of neutrophils and macrophages, improved phagocytosis and antibody-mediated immunity, and suppression of T-cell activation and proliferation are only a few of the consequences these alterations have on the immune system. The acute phase response also has metabolic implications, including mobilizing energy substrates and causing insulin resistance. These outcomes are believed to be adaptive reactions that help the body deal with the stress of tissue damage and inflammation. But excessive or protracted acute phase response activation can have pathological effects.

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Numerous chronic diseases, such as cardiovascular disease, diabetes, and cancer, have been linked to chronic low-grade inflammation, which is characterized by persistent elevation of APRs and cytokines. The interplay between the immune system, metabolic pathways, and the vasculature are among the complicated mechanisms by which chronic inflammation causes various disorders [7-11].

APRs have been researched in dermatology in relation to a number of skin conditions, such as psoriasis, atopic dermatitis, and acne. Elevated levels of APRs, such as CRP, SAA, and fibrinogen, have been seen in psoriasis and have been linked to cardiovascular risk and the severity of the disease. Elevated levels of APRs have also been seen in cases of atopic dermatitis and have been linked to both disease activity and the presence of concomitant conditions including asthma and allergic rhinitis. Elevated CRP levels have been seen in cases of acne and have been linked to both the severity of the condition and the existence of concomitant conditions like metabolic syndrome.

In conclusion, APRs are crucial in the pathophysiology of tissue damage and inflammation. The synthesis of several APRs in response to pro-inflammatory cytokines constitutes the acute phase response, a complicated systemic reaction. Depending on the environment in which they are produced, APR levels can have both physiological and pathological effects. APRs have been researched in dermatology for a number of skin conditions and have been linked to comorbid conditions and disease severity. To better understand the role of APRs in skin diseases and to create new treatments that specifically target the acute phase response, more research is required [11-15].

**The significance of APRs in dermatology**

APRs are important in dermatology because they may serve as biomarkers for different skin conditions. APR levels have been found to be elevated in a number of skin disorders, including psoriasis, atopic dermatitis, and acne, and they have been linked to both the severity of the disease and the existence of comorbid conditions [1,2].

APRs have been thoroughly investigated in psoriasis, and higher levels of CRP, SAA, and fibrinogen have been noted. The likelihood of acquiring cardiovascular disease, a prevalent comorbidity in people with psoriasis, and the severity of the disease have been observed to correspond with these markers. Elevated levels of SAA and CRP have been seen in atopic dermatitis individuals who have undergone APR studies. It has been discovered that these markers are related to disease activity and the presence of concomitant conditions including asthma and allergic rhinitis. Elevated CRP levels have been seen in cases of acne and have been linked to both the severity of the condition and the existence of concomitant conditions like metabolic syndrome [3-5].

APRs have a number of potential uses as biomarkers in dermatology. First off, APRs can offer a non-invasive way to track disease activity and treatment effectiveness. APRs can also be used to pinpoint patients who are more likely to have concomitant conditions like cardiovascular disease. This may result in earlier intervention and better patient outcomes. The use of APRs as biomarkers in dermatology does have some restrictions, though. First off, factors other than the underlying skin illness, such as age, gender, and obesity, can have an impact on the levels of APRs. APRs should therefore be interpreted in light of additional clinical and laboratory criteria. Second, it is challenging to create common reference ranges because APR levels can differ between people [10-14].

In conclusion, APRs are important biomarkers in dermatology, and their application may enhance patient outcomes and disease management. APR levels have been found to be elevated in a number of skin conditions, and they have been linked to both the severity of the disease and the existence of comorbid conditions. However, further investigation is required to establish common reference ranges, and the use of APRs as biomarkers should be understood in the context of other clinical and laboratory parameters [15-17].

**The use of APRs in the diagnosis and monitoring of skin diseases**

An area of dermatology that is rapidly developing is the use of APRs in the diagnosis and monitoring of skin diseases. APRs can help with the diagnosis, follow-up, and therapy of several skin illnesses by revealing important details about the underlying inflammatory processes in these situations. APRs have been utilized as monitoring and diagnostic techniques

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

for psoriasis. Patients with psoriasis have been reported to have elevated levels of CRP, SAA, and fibrinogen, and it has been discovered that these indicators are related to the severity of the condition and the risk of developing cardiovascular disease. Therefore, measuring the levels of these APRs can help with psoriasis diagnosis and monitoring. APRs have also been utilized as monitoring and diagnostic techniques for atopic dermatitis. Patients with atopic dermatitis have been reported to have elevated levels of SAA and CRP, and it has been discovered that these indicators are associated with the disease's activity as well as the prevalence of concomitant conditions including asthma and allergic rhinitis. Therefore, measuring the levels of these APRs can help with atopic dermatitis diagnosis and monitoring [18-20].

APRs have also been utilized as monitoring and diagnostic tools for acne. Acne sufferers have been found to have elevated levels of CRP, and these markers have been linked to both the severity of the condition and the prevalence of concomitant conditions like metabolic syndrome. Therefore, measuring the levels of these APRs can help with acne diagnosis and surveillance. There are various advantages of using APRs for skin disease diagnosis and monitoring. First off, APRs can offer a non-invasive way to track disease activity and treatment effectiveness. Second, those who are more likely to develop comorbidities like cardiovascular disease can be identified using APRs. This may result in earlier intervention and better patient outcomes [17-20].

The use of APRs in the diagnosis and monitoring of skin diseases is not without restrictions, though. Other than the underlying skin condition, factors like age, gender, and obesity can affect the levels of APRs. APRs should therefore be interpreted in light of additional clinical and laboratory criteria. Additionally, since APR levels can differ between people, it is challenging to define a set of global reference ranges. Finally, APRs can be useful diagnostic and monitoring tools for a variety of skin conditions. They can help with the identification, observation, and management of these conditions as well as offer important information about the underlying inflammatory processes. However, additional research is required to establish common reference ranges, and the use of APRs should be interpreted in the context of other clinical and laboratory parameters [20,21].

**The potential role of APRs in the development of novel therapies for dermatological diseases**

In dermatology, there is currently study being done on the possible contribution of APRs to the creation of innovative treatments for illnesses of the skin. Targeting these molecules could be a useful strategy for treating these illnesses because APRs are key players in the etiology of many skin diseases. The creation of medicines that particularly target APRs is a promising research area. For instance, rheumatoid arthritis and other inflammatory illnesses have been successfully treated with medications that target IL-6, such as tocilizumab. Similar strategies could be used to treat skin conditions by creating medications that specifically target APRs like CRP, SAA, and fibrinogen [20,21].

The use of APRs as biomarkers to identify patients who are likely to respond to particular treatments is another promising area of research. For instance, it has been demonstrated that increased CRP levels can indicate a greater response to methotrexate in psoriasis patients. Finding biomarkers like APRs may therefore make it possible to customize treatments for specific patients and enhance therapeutic effects. APRs might also be useful in the creation of personalized medicine techniques. Identifying patients with elevated levels of particular APRs, for instance, may point to a particular underlying inflammatory process that could be targeted by a particular medication. Patients with skin problems may benefit from more individualized and effective treatments as a result. Additionally, the use of APRs in clinical trials may help in the creation of fresh treatments for skin conditions. Clinical trials may be more effective and focused if individuals who are more likely to respond to a particular medication are identified by measuring their APR levels in clinical trial participants [21-23].

Overall, research is still being done to determine the potential contribution of APRs to the creation of new treatments for disorders of the skin. Targeting APRs might be a promising strategy for treating skin conditions, and identifying biomarkers like APRs might make it easier to customize treatments for different patients. To fully investigate the potential of

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

APRs in the development of innovative therapeutics for dermatological illnesses, more study is required.

## 3. Conclusion

Hepatocytes quickly produce APRs as a biomarker of systemic inflammation in response to pro-inflammatory cytokines. APRs are crucial for the diagnosis, follow-up, and prognosis of many illnesses, including dermatological conditions. The use of APRs as diagnostic and prognostic indicators can help with the management of skin conditions, and further research is needed to determine whether APRs could be the target of novel treatments for dermatological conditions.

## References

[1] Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812.

[2] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454.

[3] Jain S, Gautam V, Naseem S. Acute-phase proteins: As diagnostic tool. *J Pharm Bioallied Sci*. 2011;3(1):118-127. doi:10.4103/0975-7406.76489.

[4] Jishna P, Dominic S. Acute Phase Reactants: Relevance in Dermatology. *Indian Dermatol Online J*. 2022;14(1):1-8. Published 2022 Dec 29. doi:10.4103/idoj.idoj_174_21

[5] Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503-508.

[6] Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621-636.

[7] Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9(10):729-740.

[8] Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.

[9] Pickering MC, Walport MJ. Links between complement abnormalities and systemic lupus erythematosus. Rheumatology (Oxford). 2000;39(2):133-141. 9. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8(10):776-787.

[10] Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95(12):359-367.

[11] Gulhar R, Ashraf MA, Jialal I. Physiology, Acute Phase Reactants. [Updated 2022 Apr 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519570/.

[12] Gilliam AE. Skin signs of systemic disease in childhood. Advances in Dermatology. 2006;22:1..

[13] Biljan D, Situm M, Kostović K, Batinac T, Matisić D. Acute phase proteins in psoriasis. *Coll Antropol*. 2009;33(1):83-86..

[14] Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. *Ann Rheum Dis*. 1981;40(1):66-69. doi:10.1136/ard.40.1.66.

[15] Patel P, Werth V. Cutaneous lupus erythematosus: a review. *Dermatol Clin*. 2002;20(3):373-v. doi:10.1016/s0733-8635(02)00016-5.

[16] von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. *Br J Dermatol*. 2011;164(2):367-371. doi:10.1111/j.1365-2133.2010.10034.x.

[17] Sanad EM, El-Fallah AA, Al-Doori AR, Salem RM. Serum Zinc and Inflammatory Cytokines in Vitiligo. *J Clin Aesthet Dermatol*. 2020;13(12 Suppl 1):S29-S33..

[18] Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature.

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Journal of the European Academy of Dermatology and Venereology. 2014 Jun;28(6):700-11..

[19] Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. *Br J Dermatol*. 2020;182(5):1269-1276. doi:10.1111/bjd.18420.

[20] Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. *Clin Rev Allergy Immunol*. 2018;54(1):26-51. doi:10.1007/s12016-017-8633-4.

[21] Lee SH, Hong WJ, Kim SC. Analysis of Serum Cytokine Profile in Pemphigus. *Ann Dermatol*. 2017;29(4):438-445. doi:10.5021/ad.2017.29.4.438.

[22] Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. *Ther Adv Musculoskelet Dis*. 2013;5(5):277-285. doi:10.1177/1759720X13501021

[23] Tan M, Luo Y, Hu J, Hu K, Li X, Yang J, Chen J, Zhu W, Kuang Y. Elevated C-Reactive Protein and Erythrocyte Sedimentation Rate Correlates with Depression in Psoriasis: A Chinese Cross-Sectional Study. Clinical, Cosmetic and Investigational Dermatology. 2023 Dec 31:397-405.